a Department of Hematology and Medical Oncology , the Winship Cancer Institute of Emory University, Emory University School of Medicine , Atlanta , GA , USA.
b Department of Leukemia , the University of Texas M.D. Anderson Cancer Center , Houston , TX , USA.
Expert Rev Hematol. 2016 May;9(5):419-24. doi: 10.1586/17474086.2016.1151351. Epub 2016 Apr 21.
Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid leukemia, especially in the chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory chronic myeloid leukemia.
盐酸奥马环素已获美国食品药品监督管理局批准，用于治疗对两种或两种以上酪氨酸激酶抑制剂耐药的慢性或加速期慢性髓性白血病。本文综述了盐酸奥马环素的作用机制、药代动力学、疗效和安全性。盐酸奥马环素对慢性髓性白血病有活性，尤其是在慢性期，无论是否存在 ABL1 激酶结构域突变。盐酸奥马环素的不良反应谱独特但可管理。盐酸奥马环素是治疗部分难治性慢性髓性白血病患者的一种选择。
